Myasthenia Gravis: Finding the Right Fit in the Era of Targeted Therapy

 

Presented by

 

Zabeen Mahuwala, MD, FAAN, FACNS, FAES

Associate Professor of Neurology

Fellowship Director, Clinical Neurophysiology

Vice-Chair for Resilience and Wellness

Department of Neurology

University of Kentucky

 

Jarrett Mauk, MD

PGY3 Resident in Neurology

University of Kentucky

 

Tuesday, August 25, 2026

8:00 - 9:00 AM EDT

Zoom only: https://uky.zoom.us/j/81485627103

 

After this session, participants will be able to:

  1. Describe the evolving treatment landscape of myasthenia gravis
  2. Evaluate targeted therapies based on disease phenotype, antibody status, severity, and patient-specific factors
  3. Discuss emerging B-cell-directed and CAR-T therapies and their potential to reshape MG management

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Zabeen Mahuwala, MD, faculty for this educational event, is on scientific advisory boards for Amgen, VitaAccess Myasthenia Gravis Registry, and Janssen Biotech. She is a principle investigator for several clinical trials related to myasthenia gravis by Alexion, Argenx, Cartesian, Immunovant, RemGen, UCB, VitaAccess MG Registry, and Vor Pharmaceuticals.

All of the relevant financial relationships listed for this individual have been mitigated.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Session date: 
08/25/2026 - 12:00am EDT to 10/25/2026 - 11:59pm EDT
Add to calendar: 
  • 1.00 ACPE

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. Course JA-UAN Number: JA0000312-0000-26-056-L01-P

  • 1.00 AMA PRA Category 1 Credit™

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity. 

  • 1.00 AMA PRA Category 1 Credit™ Participation

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™ Participation. Learners should claim only credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC (UK Healthcare CECentral)

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour(s).

  • 1.00 IPCE

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Please login or register to take this course.
Faculty List: 
Speaker(s)

Zabeen Mahuwala, MD

has a financial relationship (Grant Or Contract) with Immunovant;.
has a financial relationship (Grant Or Contract) with Cartesian;.
has a financial relationship (Grant Or Contract) with VitaAccess MG Registry;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Grant Or Contract) with VOR Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with UCB;.
has a financial relationship (Grant Or Contract) with Janssen Biotech;.
has a financial relationship (Grant Or Contract) with Alexion;.
has a financial relationship (Grant Or Contract) with Argenx;.
has a financial relationship (Grant Or Contract) with RemGen;.
has a financial relationship (Grant Or Contract) with VitaAccess MG Registry;.

Jarrett Mauk

has no relevant financial relationships to disclose at this time.